The standard warning says reishi lowers blood pressure and may therefore stack dangerously with antihypertensive medication. A Cochrane review of five randomised trials covering 398 participants, and a crossover trial run specifically in people with borderline elevated blood pressure, both found no blood-pressure effect at all. The interaction everyone cautions about rests on a benefit that has not been demonstrated in humans — and the interaction that does have evidence behind it is a different one entirely.
Reishi is the mushroom most often named in blood pressure warnings, and the human evidence does not support the premise. The 2015 Cochrane review of Ganoderma lucidum for cardiovascular risk factors included five trials and 398 participants, with the analysable studies using 1.4–3 g a day for 12–16 weeks, and found no statistically or clinically significant benefit on the measured risk factors. Chu's controlled crossover trial gave 1.44 g daily for 12 weeks to 26 patients with borderline elevated blood pressure or cholesterol and reported no change in blood pressure on reishi or placebo. What does have documented interaction relevance is platelet function — reishi extract inhibited platelet aggregation in vitro more strongly than aspirin on one test — which matters because antiplatelet and anticoagulant drugs are commonly prescribed alongside antihypertensives.
Getting this the right way round matters. A warning attached to the wrong mechanism gives people false confidence about the mechanism that is real.
Where the Blood Pressure Claim Came From
From animal work and from tradition. Ganoderma lucidum has been used in East Asian medicine for cardiovascular complaints for centuries, and rodent studies have reported blood pressure effects, which is enough for a claim to propagate through supplement marketing and then into caution lists.
The human trials tell a flatter story. Klupp's 2015 Cochrane review searched broadly and with no language restriction, and found five eligible randomised or controlled trials totalling 398 participants. The three studies whose data could be pooled compared reishi at 1.4 to 3 g a day against placebo over 12 to 16 weeks, all in participants with type 2 diabetes.
The pooled results were null: no significant reduction in HbA1c (weighted mean difference −0.10%, 95% CI −1.05 to 0.85), total cholesterol, LDL cholesterol or body mass index. Risk of bias was low in one study and unclear in the other four.
Our older article on reishi and hypertension reflects the traditional framing; the Cochrane data are the better guide, and they do not support it.
The Trial Designed to Test It
Chu's 2012 study is the most directly relevant, because it recruited the exact population the warning is about. Twenty-six patients with borderline elevations of blood pressure and/or cholesterol received 1.44 g of reishi daily or matching placebo for 12 weeks in a randomised, double-blind crossover design with placebo-controlled run-in.
Among 23 evaluable subjects, there were no changes in body mass index or blood pressure on reishi or on placebo. Reishi was well tolerated.
The study did find lower plasma insulin and lower insulin resistance after reishi than after placebo, and the authors concluded that reishi might have mild antidiabetic effects. Blood pressure was simply not one of the things it moved.
The Interaction That Does Have Evidence
Platelets, not pressure. Poniedziałek's 2019 screen of eight edible mushroom species against human platelets found that Ganoderma lucidum hot-water extract inhibited aggregation induced by both ADP and arachidonic acid, exceeding 140 µmol/L of aspirin on the ADP test, while leaving prothrombin time, prothrombin ratio and INR unchanged.
That matters specifically for this readership. People treated for high blood pressure are frequently co-prescribed an antiplatelet drug — aspirin or clopidogrel — or a direct oral anticoagulant for atrial fibrillation. That is the drug class with a plausible mechanistic overlap, and unlike the blood pressure claim it has laboratory evidence behind it.
It also has an unusual blind spot: because INR is unaffected, routine monitoring will not reveal it. Our article on stopping supplements before surgery covers the same finding from the procedural side.
Cordyceps: Studied as a Partner, Not a Hazard
The one mushroom with a real clinical literature alongside antihypertensive drugs is cordyceps, and the studies used it deliberately as an add-on rather than warning about it.
Yan's 2023 systematic review and meta-analysis examined Ophiocordyceps sinensis preparations combined with ACE inhibitors or angiotensin receptor blockers in diabetic kidney disease — a population defined by being on those very drugs.
Two caveats are important. That literature is largely Chinese, heterogeneous in quality, and concerns Ophiocordyceps sinensis preparations rather than the cultivated Cordyceps militaris most Western products contain, which is a different organism with a different compound profile — see our species comparison. But the direction of that research is co-administration, not contraindication.
What the Evidence Supports, Species by Species
| Species | Blood pressure effect in humans | Real interaction concern |
|---|---|---|
| Reishi | None demonstrated — Cochrane null, crossover trial null | Antiplatelet activity; INR will not show it |
| Cordyceps | No blood pressure trials in healthy adults | Studied as an ACEI/ARB adjunct, not a hazard |
| Chaga | None | Oxalate load — relevant if kidney function is already reduced |
| Maitake | None | INR elevation with warfarin, case-reported |
| Lion's mane, Trametes, shiitake | None | No blood pressure interaction literature |
| Sea moss | Not a blood pressure product | Iodine load; thyroid disease affects blood pressure control |
Why Kidney Function Belongs in This Conversation
Because it quietly links two of the rows above. Many antihypertensive regimens include an ACE inhibitor, an ARB or a diuretic, all of which are managed around kidney function, and hypertension itself is a leading cause of chronic kidney disease.
That makes chaga's oxalate content a more relevant concern for this group than for the general population — documented at 14.2 g per 100 g in one case investigation, with two published cases of oxalate nephropathy. Our article on mushrooms, oxalates and kidney health sets out the detail.
It is an indirect interaction rather than a pharmacological one, which is exactly why it is missed.
What to Do
- Do not expect a mushroom to lower your blood pressure. The best available human evidence in the right population found no effect, so it should not be part of your management plan.
- Do not stop or reduce antihypertensive medication. Nothing here supports substituting a supplement for a drug with hard outcome data behind it.
- Tell your prescriber about reishi specifically if you take an antiplatelet or anticoagulant. That is where the documented mechanism sits.
- Do not read a normal INR as clearance. The antiplatelet effect in the screen left all three coagulation parameters untouched.
- If your kidney function is reduced, avoid chaga. The oxalate load is the relevant risk, not blood pressure.
- Check what is in a cardiovascular blend. Multi-ingredient products carry ingredients you did not evaluate — our Forest Cardio Power guide lists exactly what is in ours.
- Measure rather than assume. If you start something and want to know whether it did anything, a home blood pressure log over four weeks answers it better than any label.
The Honest Summary
The most commonly repeated mushroom-and-medication warning turns out to be attached to an effect that two good pieces of human evidence failed to find. Reishi did not lower blood pressure in a Cochrane-pooled analysis of 398 participants, and it did not lower blood pressure in a crossover trial that specifically recruited people with borderline hypertension.
That is not licence to ignore interactions; it is a redirection. The mechanism with laboratory evidence behind it is platelet inhibition, which concerns the antiplatelet and anticoagulant drugs so often prescribed alongside antihypertensives, and which the standard clotting panel does not detect. And in kidney terms, chaga's oxalate content is a more concrete concern for this population than anything on the pressure side. Tell your prescriber what you take, by name and dose, and let them weigh the mechanism that is actually documented.
Frequently Asked Questions
Does reishi lower blood pressure?
Not in the human evidence. A Cochrane review of five trials and 398 participants found no significant effect on the cardiovascular risk factors examined, and a crossover trial in 26 patients with borderline elevated blood pressure reported no change on reishi or placebo.
Can I take mushroom supplements with blood pressure medication?
There is no documented additive hypotension interaction, because the blood-pressure-lowering effect itself has not been demonstrated. The interaction worth raising with your prescriber is platelet function, particularly if you also take aspirin, clopidogrel or an anticoagulant.
Which mushroom interacts with anticoagulants?
Reishi has documented in vitro antiplatelet activity, and maitake has a published case of INR elevation when combined with warfarin. Neither is a reason for alarm, and both are reasons to disclose what you take.
Is cordyceps safe with ACE inhibitors?
The clinical literature studied the two deliberately together in diabetic kidney disease rather than as a hazard. That research largely concerns Ophiocordyceps sinensis preparations rather than the cultivated Cordyceps militaris in most Western products, which is a different organism.
Should I avoid chaga if I have high blood pressure?
Not because of the blood pressure itself, but because hypertension is a leading cause of reduced kidney function, and chaga carries an exceptionally high oxalate load with two published cases of oxalate nephropathy behind it.
Shop Cardiovascular Support Honestly
No mushroom on this site is a blood pressure treatment, and we would rather say so than sell one as if it were. Cordyceps capsules (120 caps €49) have their evidence in exercise metabolism rather than blood pressure. Forest Cardio Power (120 caps €49) is a blend whose contents are fully listed so you can check each ingredient against your own prescriptions. Reishi capsules (120 caps €39) are worth discussing with your prescriber if you take an antiplatelet drug. Free shipping on orders over €50.
Related Articles
- Reishi Side Effects and Drug Interactions
- Mushroom Supplements and Medication Interactions
- Mushroom Supplements Before Surgery
- Mushrooms, Oxalates and Kidney Health
- Reishi and Hypertension
- Cordyceps and Vascular Health
- Forest Cardio Power Guide
Sources
- Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;(2):CD007259. PubMed 25686270
- Chu TT, Benzie IF, Lam CW, Fok BS, Lee KK, Tomlinson B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr. 2012;107(7):1017-1027. PubMed 21801467
- Poniedziałek B, Siwulski M, Wiater A, et al. The effect of mushroom extracts on human platelet and blood coagulation: in vitro screening of eight edible species. Nutrients. 2019;11(12):3040. PubMed 31842490
- Yan G, Chang T, Zhao Y, et al. The effects of Ophiocordyceps sinensis combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta-analysis. Phytomedicine. 2023;108:154531. PubMed 36375237
- Lee S, Lee HY, Park Y, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122. PubMed 32419395